Psychedelic Advocacy Organizations: Who Is Pushing for Reform

MAPS: Pioneering Clinical Research and Therapeutic Frameworks

The Multidisciplinary Association for Psychedelic Studies (MAPS) was founded in 1986 by Rick Doblin, then a Harvard Kennedy School graduate student who had become convinced that psychedelics — particularly MDMA — had genuine therapeutic potential that was being suppressed by the War on Drugs. Doblin established MAPS as a nonprofit pharmaceutical company with a single long-term goal: obtain FDA approval for psychedelic-assisted therapies by rigorously following the drug development pathway. This meant funding, designing, and publishing peer-reviewed clinical trials at a time when no institutional funder would touch the subject.

MAPS's most consequential achievement has been its MDMA-assisted therapy program for post-traumatic stress disorder (PTSD). After decades of Phase 1 and Phase 2 trials demonstrating safety and preliminary efficacy, the FDA granted MDMA a Breakthrough Therapy Designation in 2017 — a classification that expedites development and review for conditions with unmet medical need. MAPS completed two Phase 3 trials (MAPP1 and MAPP2), both showing statistically significant reductions in PTSD symptom severity compared to placebo plus therapy. A New Drug Application was submitted in late 2023. Though the FDA's advisory committee raised questions about blinding and functional unblinding in the trial data in 2024, the program remains the most advanced psychedelic drug development effort in regulatory history.

Beyond MDMA, MAPS funds and supports research into psilocybin and LSD. The organization published the first peer-reviewed training protocol for psychedelic-assisted psychotherapy, establishing a model for how therapists should prepare, support, and integrate sessions with patients. MAPS is headquartered in San Jose, California, and operates MAPS Public Benefit Corporation (MAPS PBC) as its for-profit subsidiary responsible for commercializing approved therapies.

Drug Policy Alliance: Electoral Wins and Harm Reduction Curriculum

The Drug Policy Alliance (DPA) was founded in 2000 by Ethan Nadelmann through a merger of the Drug Policy Foundation and the Lindesmith Center. Nadelmann, a former Princeton and Harvard scholar, had become the most prominent American voice for drug policy reform throughout the 1990s, arguing that prohibition caused more harm than the drugs themselves. The DPA operates at the intersection of electoral politics, legislative advocacy, litigation, and harm reduction education, with an annual budget exceeding $30 million.

The DPA's electoral work produced two landmark victories for psychedelic reform. Oregon Measure 110, passed by voters in November 2020, decriminalized personal possession of all drugs and redirected cannabis tax revenue to treatment and harm reduction — the first statewide drug decriminalization measure in U.S. history. The DPA was a primary backer and organizer. Colorado Proposition 122, passed in November 2022, went further: it decriminalized personal use, possession, and limited sharing of psilocybin, psilocin, DMT, ibogaine, and mescaline, and created a regulatory framework for licensed "healing centers" where facilitated psilocybin experiences became legal for adults beginning in 2024. The DPA supported this initiative as well, though the Colorado campaign was primarily led by Natural Medicine Colorado.

The DPA also produces the "Safety First" harm reduction curriculum, a widely used educational program distributed to schools and community organizations that advocates for evidence-based drug education over abstinence-only messaging. The curriculum covers cannabis, stimulants, opioids, and psychedelics, providing factual information about risks and safer use practices. Kassandra Frederique served as executive director of the DPA from 2021, continuing Nadelmann's tradition of centering racial equity and criminal justice in the drug policy reform conversation.

Students for Sensible Drug Policy and Decriminalize Nature

Students for Sensible Drug Policy (SSDP) was founded in 1998 as a campus-based organization dedicated to training the next generation of drug policy reformers. With chapters at more than 300 universities and colleges across the United States and internationally, SSDP organizes students to advocate for harm reduction at their schools, challenge campus drug policies, and engage in local and national legislative campaigns. The organization hosts an annual conference that brings together students, researchers, advocates, and policymakers, and it has been a significant pipeline for activists who later lead major reform organizations. SSDP's work helped repeal the Higher Education Act drug provision, which had stripped federal financial aid from students with drug convictions.

Decriminalize Nature emerged from a different tradition. Founded in 2019 in Oakland, California, by Carlos Plazola and a coalition of activists, it authored the first municipal resolution in the United States to decriminalize entheogenic plants and fungi, passed by the Oakland City Council in June 2019. The resolution directed law enforcement to make investigation and arrest of adults for use or possession of entheogenic plants — including psilocybin mushrooms, ayahuasca, iboga, and peyote — among the city's lowest priorities. The model resolution spread rapidly: Denver had already passed a psilocybin-specific initiative in May 2019 (the first U.S. jurisdiction to do so), and Decriminalize Nature helped bring similar measures to Washington D.C. (2020), Santa Cruz (2020), Ann Arbor (2020), Seattle (2021), and a growing list of cities.

Decriminalize Nature's framing is deliberately broader and more culturally rooted than the pharmaceutical approach favored by MAPS. It uses the language of "natural medicines" and emphasizes indigenous relationships with plant and fungal medicines, community access, and decriminalization over medicalization. This distinguishes it from advocates who focus primarily on FDA approval pathways and clinical therapy frameworks, and has generated productive tension within the psychedelic reform ecosystem about the relative merits of decriminalization versus regulated medical access.

Chacruna Institute and Psychedelic Alpha: Bridging Indigenous and Academic Worlds

The Chacruna Institute for Psychedelic Plant Medicines was founded by anthropologist Beatriz Caiuby Labate, one of the world's leading scholars of ayahuasca and psychedelic policy. Chacruna occupies a distinctive position in the advocacy landscape: it bridges indigenous communities, academic researchers, therapists, and policy advocates, insisting that the commercialization and medicalization of psychedelics cannot be ethically separated from questions of indigenous sovereignty, cultural appropriation, and benefit-sharing with the communities that have stewarded these medicines for centuries.

Chacruna publishes educational articles, hosts conferences, runs a professional training program for psychedelic therapists that centers cultural competency, and advocates for indigenous intellectual property rights. Its "Indigenous Reciprocity Initiative of the Americas" raises funds to support indigenous communities whose traditional plant medicines are now being commercialized by Western biotech companies — raising ethical questions the mainstream psychedelic industry has been slow to address.

Psychedelic Alpha, founded by Josh Hardman, serves as the primary analytical and media outlet covering the psychedelic industry from a business and regulatory perspective. While not an advocacy organization in the traditional sense, Psychedelic Alpha has become an indispensable reference for investors, clinicians, and policymakers tracking the commercial development of psychedelic medicines, the competitive landscape of drug development, and the regulatory decisions shaping the field. Its detailed coverage of FDA advisory committee meetings, clinical trial progress, and state regulatory developments provides a level of rigor and transparency that supports informed public debate about psychedelic reform.

Frequently Asked Questions

What is MAPS and what has it accomplished?

The Multidisciplinary Association for Psychedelic Studies (MAPS) is a nonprofit pharmaceutical organization founded in 1986 by Rick Doblin. Its primary accomplishment is sponsoring the Phase 3 clinical trials of MDMA-assisted therapy for PTSD, which led to the FDA's Breakthrough Therapy Designation in 2017 and a New Drug Application in 2023. MAPS also funds psilocybin and LSD research, publishes therapist training protocols, and has been the most consequential single organization in demonstrating that psychedelics can be rigorously studied within conventional pharmaceutical development frameworks.

What is the Drug Policy Alliance's role in psychedelic reform?

The Drug Policy Alliance (DPA) is a policy advocacy and electoral organization that has supported multiple psychedelic decriminalization initiatives, most notably Oregon Measure 110 (2020) and Colorado Proposition 122 (2022). With an annual budget over $30 million, the DPA operates at the intersection of racial justice, harm reduction, and drug policy, and it produces widely used educational materials like the "Safety First" curriculum. It approaches drug reform through a broad lens that includes decriminalization of all substances, not just psychedelics.

What did Decriminalize Nature achieve?

Decriminalize Nature authored the first municipal resolution to decriminalize entheogenic plants and fungi in Oakland, California in June 2019. It then spread this model to Washington D.C., Santa Cruz, Ann Arbor, Seattle, and numerous other cities. Its approach prioritizes decriminalization of natural medicines at the local level, emphasizes indigenous traditions, and uses a "natural medicines" framing that distinguishes it from the pharmaceutical-oriented approach of organizations like MAPS.

What is the Chacruna Institute?

The Chacruna Institute for Psychedelic Plant Medicines, founded by anthropologist Beatriz Caiuby Labate, bridges indigenous communities, academic researchers, and policy advocates. It focuses on the ethical dimensions of psychedelic commercialization, including indigenous sovereignty, cultural appropriation, and benefit-sharing. Chacruna publishes educational materials, runs cultural competency training for psychedelic therapists, and advocates for indigenous communities whose traditional medicines are being commercialized by Western companies.

How does Students for Sensible Drug Policy differ from other advocacy groups?

SSDP is a campus-based organization with chapters at 300+ universities that focuses on training student activists and reforming campus-level drug policies. It serves as a pipeline for the next generation of drug policy reformers and has achieved concrete policy wins such as helping repeal the Higher Education Act provision that stripped federal financial aid from students with drug convictions. Its approach is grassroots and student-led, in contrast to organizations that focus primarily on legislative lobbying or clinical research.

What was Oregon Measure 110?

Oregon Measure 110, passed by voters in November 2020, was the first statewide drug decriminalization measure in U.S. history. It reclassified personal possession of small amounts of all drugs from a criminal offense to a civil violation (a $100 fine, waived upon completion of a health assessment) and redirected cannabis tax revenue to fund addiction treatment and harm reduction services. The measure was backed by the Drug Policy Alliance and passed with 58% of the vote.

What is Colorado Proposition 122?

Colorado Proposition 122 (the Natural Medicine Health Act), passed in November 2022, decriminalized personal use, possession, and limited sharing of psilocybin, psilocin, DMT, ibogaine, and mescaline for adults over 21. It also created a regulatory framework for licensed "healing centers" where facilitators can legally guide adult psychedelic experiences, which began operating in 2024. It was the broadest statewide psychedelic decriminalization measure passed in the U.S. and included multiple natural psychedelic substances rather than psilocybin alone.

What is MAPS PBC?

MAPS Public Benefit Corporation (MAPS PBC) is the for-profit subsidiary of MAPS responsible for commercializing FDA-approved psychedelic therapies. It was created to raise investment capital for the expensive Phase 3 trial process while maintaining MAPS's nonprofit mission. If MDMA-assisted therapy receives FDA approval, MAPS PBC would be responsible for manufacturing, distribution, and training programs. The dual structure — nonprofit parent, for-profit subsidiary — has been influential as a model for how mission-driven psychedelic companies might operate.

Are these organizations legal in the United States?

Yes. All of the advocacy organizations described here operate legally as nonprofit organizations, educational institutions, or policy advocacy groups. Advocacy for drug policy reform — including legalization and decriminalization — is protected political speech under the First Amendment. These organizations do not distribute controlled substances; they conduct education, fund research through legal channels, and engage in electoral and legislative advocacy within the law.

How can I support psychedelic advocacy organizations?

Most major advocacy organizations accept donations through their websites. MAPS, the Drug Policy Alliance, Decriminalize Nature, Chacruna Institute, and SSDP all have donation portals. Beyond financial support, you can volunteer with local chapters (especially SSDP if you are a student), contact elected representatives in support of reform measures, participate in public comment periods on regulatory proposals, and support local decriminalization initiatives when they appear on ballots. Staying informed through publications like Psychedelic Alpha and following reliable scientific reporting are also important forms of civic engagement in this space.